D a t a s o u r c e s
Studies were identified by searching MED-LINE (1966 to 2000) and bibliographies of relevant studies and reviews.
S t u d y s e l e c t i o n
2 reviewers independently selected Englishlanguage randomized controlled trials (RCTs) that compared medications for intensive risk-factor reduction with placebo or routine risk-factor reduction in adults with type 2 diabetes; had ≥ 10 patients in each group; followed patients for ≥ 1 year; and reported on ≥ 1 of aggregate cardiac events, cardiovascular mortality, all-cause mortality, myocardial infarction, and stroke. Exclusion criteria were nonpharmacologic treatments, absence of prespecified outcomes, or comparing therapeutic agents rather than evaluating risk-factor lowering.
D a t a e x t r a c t i o n
Data were extracted on patients, treatment, CVD history, diabetes duration, risk-factor levels, and outcome events.
M a i n r e s u l t s 7 cholesterol-lowering RCTs (2603 diabetic patients, mean age 58 y, 87% men), 6 blood pressure-lowering RCTs (7572 diabetic patients, mean age 62 y, 57% men), and 5 glucose-lowering RCTs (5159 diabetic patients, mean age 57 y, 59% men) were included. Mean follow-up ranged from 4.3 to 6.1 years for cholesterol-lowering RCTs, 2.0 to 8.4 years for blood pressure-lowering RCTs, and 1.0 to 12.5 years for glucose-lowering RCTs. Pooled results showed that lowering cholesterol levels and blood pressure reduced cardiac event rates; the lowering of glucose levels did not reduce cardiac event rates (Table) . When cholesterol-lowering RCTs were classified as primary prevention or secondary prevention, the effect remained for secondary-prevention RCTs (3 RCTs) but not for primary-prevention RCTs (2 RCTs) (Table) .
C o n c l u s i o n s
In patients with type 2 diabetes mellitus, medications to lower cholesterol levels or blood pressure substantially reduce cardiovascular disease (CVD). Medications to lower glucose levels appear to have less, if any, effect on CVD. 
C o m m e n t a r y
Despite a well-known increase in the incidence of CVD in patients with type 2 diabetes, the relative effect of glycemic control, cholesterol lowering, and blood pressure control with medications remains controversial. In their meta-analysis, Huang and colleagues show that while cholesterol-lowering and blood pressure-lowering drugs reduced the risk for cardiac events, the risk reduction with glucose-lowering agents was not statistically significant. The interpretation of these findings is fraught with uncertainties in view of the following caveats. First, as pointed out by the authors, the underlying cardiovascular status of patients in each of the 3 interventions differed: The percentages of patients with coronary artery disease in the cholesterol-, blood pressure-, and glucose-lowering RCTs were 89%, 32%, and 13%, respectively. Consequently, the lowest event rates in the control groups of the glucose-lowering RCTs reflected the lowest absolute risk for events in patients with such underlying disease. Only 2 of the 5 glucose-lowering RCTs, both targeted at primary prevention, provided aggregate cardiac end points. In fact, in the only secondary glucose-lowering RCT included in this analysis, the reduction in cardiovascular mortality was statistically significant. However, it was a relatively short-term RCT. Second, the mean fasting plasma glucose reduction of 29 mg/dL and mean glycosylated hemoglobin (HbA 1c ) reduction of 0.9% achieved in the glucose-lowering trials may not sufficiently improve the glycemic burden. Finally, the effects of newer insulin-sensitizing agents (e.g., thiazolidinediones), with potential benefits for atherogenesis or vascular function, were not studied.
Epidemiologic evidence continues to show that the increased risk for CVD extends well into the moderately increased range of glycemia (HbA 1c < 7.0%) (1). Thus far, none of the RCTs available have fully tested the glucose-lowering hypothesis. Currently, 2 large trials aiming for tighter glucose control with various pharmacologic agents, including insulin sensitizers, are being done (2, 3) . Furthermore, despite evidence for reduced cardiovascular events with cholesterol-and blood pressure-lowering medications, the residual risk in diabetic patients treated to current target levels remains unacceptably high.
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